ESTRELLA IMMUNOPHARMA, INC.: 10-Q filed 2023-08-01

Name: ESTRELLA IMMUNOPHARMA, INC.: 10-Q filed 2023-08-01
Creator: ESTRELLA IMMUNOPHARMA, INC.

What ESTRELLA IMMUNOPHARMA, INC. reported in its quarterly report filed 2023-08-01 (fiscal Q2 2023): 18 published measures, 46 facts as tagged in accession 0001213900-23-061563.

This filing

Form: 10-Q (quarterly report)
Filed: 2023-08-01
Fiscal period: fiscal Q2 2023
Accession: 0001213900-23-061563 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All ESTRELLA IMMUNOPHARMA, INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

Period	Value	Unit	Days
At 2023-06-30	9,921,634	USD
At 2022-12-31	9,723,802	USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

Period	Value	Unit	Days
At 2023-06-30	2,990,202	USD
At 2022-12-31	2,653,041	USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

Period	Value	Unit
At 2023-06-30	-2,820,571	USD
At 2023-03-31	-2,528,743	USD
At 2022-12-31	-2,255,685	USD
At 2022-06-30	-1,507,030	USD
At 2022-03-31	-1,147,444	USD
At 2021-12-31	-1,006,192	USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

Period	Value	Unit	Days
At 2023-06-30	34,688	USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

Period	Value	Unit	Days
2023-04-01 to 2023-06-30	-76,004	USD	91
2023-01-01 to 2023-06-30	-139,329	USD	181
2023-01-01 to 2023-03-31	-63,325	USD	90
2022-04-01 to 2022-06-30	-359,586	USD	91
2022-01-01 to 2022-06-30	-500,838	USD	181
2022-01-01 to 2022-03-31	-141,252	USD	90

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

Period	Value	Unit	Days
2023-01-01 to 2023-06-30	-488,384	USD	181
2022-01-01 to 2022-06-30	-390,587	USD	181

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

Period	Value	Unit	Days
2023-01-01 to 2023-06-30	383,066	USD	181

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

Period	Value	Unit	Days
2023-01-01 to 2023-06-30	99,204	USD	181

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

Period	Value	Unit	Days
At 2023-06-30	-2,820,713	USD
At 2022-12-31	-2,255,827	USD

Income tax expense or benefit

Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.

Period	Value	Unit	Days
2023-04-01 to 2023-06-30	21,077	USD	91
2023-01-01 to 2023-06-30	40,542	USD	181

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

Period	Value	Unit	Days
2023-04-01 to 2023-06-30	-169,237	USD	91
2023-01-01 to 2023-06-30	-318,887	USD	181
2022-04-01 to 2022-06-30	-423,765	USD	91
2022-01-01 to 2022-06-30	-568,705	USD	181

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

Period	Value	Unit	Days
At 2023-06-30	129,363	USD
At 2022-12-31	52,427	USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

Period	Value	Unit	Days
At 2023-06-30	1,431,332	USD
At 2022-12-31	1,073,069	USD

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

Period	Value	Unit	Days
At 2023-06-30	1,419,700	shares
At 2022-12-31	1,419,700	shares

Cash including restricted cash

Cash, cash equivalents and restricted cash as reported in the cash flow reconciliation. Restricted amounts are not freely available, so this is not the same as unrestricted cash.

Period	Value	Unit
At 2023-06-30	34,688	USD
At 2022-12-31	40,802	USD
At 2022-06-30	88,281	USD
At 2021-12-31	478,868	USD

Net deferred tax liabilities

Deferred tax liabilities net of related assets under this concept. The amount reflects timing differences and is not tax currently due.

Period	Value	Unit	Days
At 2023-06-30	8,370	USD
At 2022-12-31	29,472	USD

Pre-tax income or loss from continuing operations

Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.

Period	Value	Unit	Days
2023-04-01 to 2023-06-30	-54,927	USD	91
2023-01-01 to 2023-06-30	-98,787	USD	181
2022-04-01 to 2022-06-30	-359,586	USD	91
2022-01-01 to 2022-06-30	-500,838	USD	181

Deferred income tax expense or benefit

The deferred portion of income tax expense or benefit, arising from timing differences. It is not tax paid in the period.

Period	Value	Unit	Days
2023-01-01 to 2023-06-30	-21,102	USD	181

Inspect the source

Entity: ESTRELLA IMMUNOPHARMA, INC. / CIK 0001844417
Captured: 2026-09-21T17:30:17.565Z
SEC response SHA-256: 0d6a09fe04855c71f90123cc6e30e8f7f9e3767836b4d533de9056afed987397

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python

import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001844417.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))